… promise in reducing Parkinson’s disease risk. Microbiome-… of neurotransmitters, including
GABA, which is a target of … as they can modulate dopaminergic neurotransmission in the brain. …

… Several risk factors are associated with Parkinson’s disease … facilitating neural plasticity of
targeted brain regions, potentially … an increased release of dopamine neurotransmitter in brain …

… of multiple sclerosis and Parkinson’s disease. In the brains of … Two months of wheel running
restored neurotransmission to … usefulness of therapeutic strategies targeting microglia. The …

… targets passed 14 metabolic pathways, mainly involved in the regulation of neurotransmitters
(5-hydroxytryptamine, dopamine … that 3 targets were closely related to Parkinson's disease (…

… ’s disease, multiple sclerosis, or Alzheimer’s disease. Given … diseases will result in disruptions
of neurotransmitter function … surrounding the targeting of CPT1A and its implications for …

… ’s disease pathology. The major hallmark of Parkinson’s disease is the loss of dopaminergic
… deficits, motivating researchers to identify therapeutic agents targeting these mechanisms. …

… Parkinson’s disease is a neurodegenerative condition … ie, a major dopamine target area) or
spinal cord (ie, a non-target area) cells. … between the serotonergic and other neurotransmitter …

… neurotransmitters such as dopamine, leading to toxic metabolites that are enriched both in
diabetic animal models and in Parkinson’s disease … target against AGEs-associated disorders. …

… neurotransmitter system associated with cognitive function of the cerebellum in Parkinson’s
disease… mechanisms and explore new therapeutic targets for transcranial magnetic therapy. …

… diseases, such as Alzheimer’s or Parkinson’s disease, dementia… therapies to target
immune-related neurological diseases, such … of neurotransmitters and hormones, such as …